Sugi Predict

Sugi Predict / Compounds / SCHEMBL3484306

SCHEMBL3484306

SCHEMBL3484306

CCCc1ccc(OC)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 3/20 0.44
▸ HTR2C P28335 2/20 0.44
▸ APLNR P35414 1/20 0.43
▸ ADRA1A P35348 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ ESR1 P03372 1/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ HMGCR P04035 1/20 0.40
▸ CRHR1 P34998 1/20 0.40
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA14 Q9ULX7 2/20 0.39
▸ ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15376943 0.86 HTR1A (0.45) HTR2AHTR2CADRA1ATAAR1
SCHEMBL13802275 0.83 ADRA1A (0.48) APLNRADRA1ATAAR1POLBHMGCR
SCHEMBL3484107 0.83 APLNR (0.46) HTR2AHTR2CAPLNRADRA1ATAAR1
SCHEMBL32684300 0.82 TAAR1 (0.62) HTR2AHTR2CADRA1ATAAR1
SCHEMBL10345905 0.82 TAAR1 (0.62) HTR2AHTR2CADRA1ATAAR1
SCHEMBL23704945 0.82 HTR2A (0.43) HTR2AHTR2CAPLNRADRA1ATAAR1
SCHEMBL17410211 0.82 CYP2D6 (0.53) HTR2AHTR2CAPLNRADRA1ATAAR1
SCHEMBL24959992 0.82 HTR2A (0.43) HTR2AHTR2CAPLNRADRA1ATAAR1
Ammonia Solution, Strong SCHEMBL10346000 0.82 APLNR (0.44) HTR2AHTR2CAPLNRADRA1ATAAR1
SCHEMBL9917312 0.80 KMT2A (0.48) APLNRADRA1ATAAR1POLBESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 — — US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 — — US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 — — US disclosed
CN-101522192-A Substituted imidazolone derivatives, preparation and uses GENFIT (FR) 2009-09-02 — — CN disclosed
EP-2049107-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES Genfit (FR) 2009-04-22 — — EP disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 — — WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 HTR2A 2456/4885HTR2C 1099/4885APLNR 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.